What ORTHOVISC Treats: Main Uses and Benefits

ORTHOVISC is a treatment categorized as viscosupplementation, primarily indicated for managing symptoms associated with knee pain due to osteoarthritis (OA). This therapy is typically utilized in patients whose symptoms persist despite the use of non-pharmacologic measures (such as exercise) and simple pain relief medications.

The primary purpose of ORTHOVISC is to help manage symptoms of pain in the knee caused by OA. The treatment may help relieve symptoms of joint discomfort and can support joint movement.

“The treatment is designed to help support the function of the affected joint.”

Quick Fact: Support for Knee Pain

The treatment is used in connection with pain in the knee resulting from joint degeneration, such as established osteoarthritis or related painful conditions.

Regulatory References

1. SUMMARY OF SAFETY AND EFFECTIVENESS DATA GENERAL INFORMATION Device Generic Name: Sodium hyaluronate Device Trade Name: ORTHOVIS - accessdata.fda.gov

Eligibility Map: Who can and cannot use ORTHOVISC

This section defines eligibility strictly according to official government regulatory information, outlining which populations are permitted or restricted from using the product.

---

Eligibility Scope

Category	Regulatory Status
Populations for whom use is allowed	Adult patients with pain from osteoarthritis (OA) of the knee who have failed conservative, non-pharmacologic therapy and simple analgesics.
Populations for whom use is contraindicated	Patients with known hypersensitivity to hyaluronate preparations or to avian-derived products (e.g., eggs, poultry). It is also contraindicated if there are infections or skin diseases in the area of the injection site.
Age-related eligibility rules	The safety and effectiveness of the use of ORTHOVISC have not been established in children (pediatric patients).
Pregnancy and lactation eligibility status	Safety and effectiveness have not been established in pregnant women or nursing mothers.
Eligibility-related restrictions	The product is only approved for use in the knee joint; safety and effectiveness have not been demonstrated in other anatomical locations. Severe intra-articular effusion (excess joint fluid) must be removed before injection.

---

Connection to the overall eligibility profile

Official regulatory documents define the eligible group as adults with knee OA who have failed initial conservative treatment. They establish clear boundaries by contraindicating use for patients with specific allergies or active local infections. Furthermore, use is not established for children or during pregnancy and lactation, thereby restricting treatment to the established adult demographic.

Interaction Map: Interactions with other medicines and products — official regulatory information for ORTHOVISC

The official regulatory documents for ORTHOVISC, a non-systemic intra-articular solution, define its interaction profile based on procedural constraints rather than systemic drug–drug interactions. Due to the product's highly localized action, interactions related to metabolic enzymes (such as CYP450) or drug transporters are not described in official labeling.

---

Interaction Scope

Category	Substance and Regulatory Description
Product Categories Identified	Disinfectants containing Quaternary Ammonium Salts (e.g., benzalkonium chloride).
Mechanistic Basis	Chemical Precipitation of the hyaluronic acid component (Local chemical incompatibility).
Timing-based Interaction Rules	Incompatible skin disinfectants must not be used concomitantly during the administration procedure.

---

Interaction Classifications (High-Level)

Classification	Regulatory Description
Interaction Severity	Mandatory Restriction / Contraindicated Co-use (Due to physical alteration of the drug).
Interaction-Context Constraints	Local administration/procedural constraint.

---

Resulting Interaction Structure

The primary documented restriction is a procedural constraint requiring the exclusion of certain chemical substances from the injection site preparation. Regulatory information explicitly states that the co-use of disinfectants containing quaternary ammonium salts is prohibited. This restriction is necessary because these agents cause the hyaluronic acid component to clump and lose integrity. This administrative limitation ensures the product remains physically suitable for its intended viscoelastic function.

ORTHOVISC functions as a viscosupplement through direct interaction within the synovial space of a diarthrodial joint, specifically targeting the extracellular matrix of the articular cartilage and synovial fluid. The active molecular component is high molecular weight hyaluronan (HA), a long-chain polysaccharide that is a native constituent of the synovial fluid.

Following intra-articular administration, the exogenous HA molecules integrate with the endogenous HA network, restoring the rheological properties—viscosity and elasticity—of the synovial fluid. This mechanical integration increases the fluid’s capacity for load-bearing and energy dissipation within the joint.

At the tissue level, the augmented viscoelasticity provides enhanced lubrication for the opposing articular cartilage surfaces. The HA molecules also accumulate within the superficial zone of the articular cartilage, forming a protective boundary layer. This localized action serves to modulate mechanical stress transmission across the joint articulation, resulting in systemic-level biomechanical stabilization of joint function.

How ORTHOVISC is Used: Official Administration Guidelines

ORTHOVISC is a viscosupplement administered under strict procedural guidelines, ensuring its proper, non-systemic delivery directly into the joint.

Administration Scope

Attribute	Official Label Instructions
Route of Administration	Intra-Articular Injection (directly into the joint space).
Injection Site	Approved for administration only into the knee joint.
Standard Dose	30 mg (the full contents of one 2 mL syringe) per injection.
Frequency	Once a week.

Treatment Course and Procedural Requirements

ORTHOVISC treatment is structured as a single, time-limited course, with specific steps required before and after the injection:

• Total Course Duration: A complete treatment course consists of a total of 3 or 4 weekly injections. The safety and effectiveness of using more than one course of treatment have not been established.
• Pre-Injection Step: If excess fluid (effusion) is present in the knee, it must be removed (aspirated) before the ORTHOVISC injection is administered.
• Administration Technique: The procedure must be performed by a qualified professional using a strict aseptic injection technique. Disinfectants containing quaternary ammonium salts should not be used for skin preparation.
• Post-Injection Activity: Patients are instructed to avoid strenuous or prolonged weight-bearing activities (such as jogging, tennis, or heavy lifting) for at least 48 hours following the injection.

Age Restriction: The product is not approved for use by anyone younger than 21 years old.

ORTHOVISC: Recent Clinical Evidence

---

Research Evidence for Knee Pain due to Osteoarthritis (OA)

The clinical evaluation of ORTHOVISC was studied in the research context of knee pain associated with osteoarthritis (OA). This evidence is primarily based on Randomized Controlled Trials (RCTs), where the product was compared against control groups, such as an intra-articular saline injection or arthrocentesis. These trials focused on outcomes related to physical discomfort and daily functioning, measuring changes using validated patient-reported scales.

The evidence base describes patterns that were observed in these controlled settings. However, regulatory reviews indicate that some individual, initial trials reported mixed findings on the primary outcome compared to the saline control. Claims regarding the primary outcomes were derived from analysis of combined data from multiple trials and specific patient groups observed in some studies. This research describes patterns studied in patients who had not responded to initial conservative measures.

---

Long-Term Evidence and Areas of Uncertainty

The key trials supporting the product’s evaluation typically monitored patients for periods extending up to intermediate-term durations of approximately six to seven months. The long-term patterns of change are not fully established beyond this duration. There is limited information regarding how the observed changes may persist over longer periods, and data are still emerging regarding the assessment when the product is used in repeat courses of treatment.

The clinical trials primarily examined adults whose radiographic assessment placed them in the mild to moderate radiographic findings range. Research concerning patients with severe osteoarthritis is not well characterized in the key studies supporting initial regulatory clearance. The overall consistency of findings varies across studies, and the certainty remains low for long-term patterns of change.

Common questions about ORTHOVISC (FAQ)

Q: How is ORTHOVISC different from a traditional steroid injection?

ORTHOVISC is classified as a viscosupplement, not a corticosteroid or steroid injection. Official information indicates its hyaluronic acid component works mechanically to restore the natural viscosity and elasticity of the joint fluid, aiding lubrication and shock absorption. This action is chemically different from that of anti-inflammatory steroid medicines.

---

Q: Are there any restrictions on driving right after receiving an ORTHOVISC injection?

Official post-injection guidance advises avoiding strenuous activities and prolonged weight-bearing for at least 48 hours. However, routine activities like driving or walking are generally permitted immediately following the injection. If significant pain or stiffness is experienced in the knee, waiting until this has eased is generally advised.

---

Q: Can I take my regular pain medication before or after an ORTHOVISC injection?

According to official regulatory documents, ORTHOVISC acts locally within the knee joint. Systemic drug-drug interactions with common oral pain medications, such as acetaminophen or ibuprofen, are not specifically reported. Information regarding personal medication schedules related to the procedure is typically determined by a healthcare provider.

---

Q: What is the molecular weight of the ingredient in ORTHOVISC?

The active component, hyaluronic acid, is defined as a high molecular weight product. Regulatory documents report its molecular weight to be in the range between 1 and 2.9 million Daltons. This specific high molecular weight is intended to closely match the properties of healthy joint fluid.

---

Q: What percentage of patients in clinical trials reported general side effects?

Clinical trial data included in official information reports the incidence of general side effects. For example, common reactions like arthralgia (joint pain) were reported by 12.6% of patients, and headache was reported by 12.1% of patients in the ORTHOVISC group.

---

Q: How often is the ORTHOVISC series typically repeated?

Official information notes that the safety and effectiveness of repeat courses have been examined in studies. The initial treatment is typically given as a single course; however, repeat courses have been assessed in studies after the initial period of pain relief, which is reported to last up to six months, has diminished.

---

Q: Is the injection procedure itself generally painful?

According to patient information and clinical guidance, it is possible to experience a short period of discomfort or pain while the injection is being administered. This sensation is typically brief and goes away quickly.

---

Q: Are there different formulations of ORTHOVISC available globally?

While ORTHOVISC is the specific multi-injection formula, the same grade of hyaluronic acid is used in other related products globally. One such product is MONOVISC, which is a single-injection treatment that utilizes the same quality of active ingredient.

---

Q: What is the maximum duration of relief reported in some studies?

Studies summarized in the official product claims indicate that ORTHOVISC can provide relief from joint pain for periods lasting up to six months (26 weeks). The duration of this relief may vary among individuals.

---

Q: Is it possible for the injection site reaction to last longer than a week?

Official documentation describes common local side effects such as pain, swelling, and redness as transient, meaning they are temporary and short-lived. These reactions typically resolve within 48 hours to a few days after the injection.

---

Q: Can ORTHOVISC be used by athletes or people with very physically demanding jobs?

Official post-injection instructions advise that strenuous activities and prolonged weight-bearing activities (lasting more than one hour) are to be avoided for at least 48 hours following the injection. Beyond this initial period, individuals are generally able to resume their normal activities.

---

Q: What are the key points of the Patient Information Leaflet for ORTHOVISC?

Key points generally advise patients to avoid strenuous activities for 48 hours after the injection. They also state that the product should not be used if a local infection is present, and reporting persistent or worsening pain to a healthcare professional is advised.

Storing and Disposing of ORTHOVISC

The storage and disposal of ORTHOVISC (sodium hyaluronate) must strictly follow the official instructions provided in the regulatory labeling to maintain product sterility and integrity.

---

Storage Conditions

ORTHOVISC must be stored at controlled room temperature, specifically between 2 C and 25 C (36 F to 77 F). It is mandatory to DO NOT FREEZE the solution. The product must remain in its original package until the time of use to ensure protection. Do not use the syringe if the package has been opened or appears damaged, as this compromises sterility. As with all medicines, keep ORTHOVISC out of the sight and reach of children.

---

Handling and Disposal

ORTHOVISC is a single-use sterile product, and the contents must be administered immediately after opening. Do not resterilize the syringe. Any unused portion of the product must be discarded according to the local regulations for medical waste.